ExploRNA’s proprietary technology

ExPLoRNA Therapeutics presents a family of compounds inspired by biology. Our vast library of cap analogs offers unprecedented opportunity to create tailor made mRNA for vaccines and therapeutics products.

 Our two lead products are ExploCap® and AvantCap®.

mRNA has also emerged as both a disruptive and highly promising technology providing access to new class of medicines

DNA stores instructions for proteins in the nucleus

mRNA is a temporary set of instructions for cells to make proteins

Proteins form the basis of life by performing the functions required by every cell

Using mRNA as a therapeutic is a cutting-edge approach

mRNA based drugs deliver a defined generic message into the cells to produce any kind of protein

Ability to set instruction for cells allows mRNA therapeutics to be used for any disease

mRNA drugs have potential to transform standards of drug discovery and manufacturing

mRNA consist of the coding region, which contains all the information about protein sequence, and several regulatory elements that stabilize mRNA and guide protein production machinery to mRNA.

These elements include mRNA cap at the 5′ end and polyA tail at the 3′ end of mRNA.

mRNA-based therapeutics

mRNA technology has emerged as both a disruptive and highly promising new class of medicines.

The new mRNA technology innovations, combined with the unique know-how of ExploRNA’s scientific team, provide a unique opportunity to harness this cutting-edge technology to revolutionize therapy and prevention of many diseases.

ExploRNA’s two lead development programs are focusing on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth.

Modified mRNA has a wide range of applications which represent a significant market opportunity

mRNA has the potential to treat any disease where expression of protein(s) will drive the alleviation of the symptoms or causes of the disease.

Scientific publications

Featured Publications

mRNA 5’ cap modifications

Trinucleotide mRNA Cap Analogue N6-Benzylated at the Site of Posttranscriptional m6Am Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo

Intellectual property

A strong intellectual property position based on science excellence

International patents

WO2017130151A1

5'-phosphorothiolate mRNA 5'-end (cap) analogs, mRNA comprising the same, method of obtaining and uses thereof

WO2018015845

Novel phosphotriazole mRNA 5'-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide

WO2017130151A1

5'-phosphorothiolate mRNA 5'-end (cap) analogs, mRNA comprising the same, method of obtaining and uses thereof

WO2018015845

Novel phosphotriazole mRNA 5'-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide

WO2021162566

Novel mRNA 5'-end cap analogs modified within phosphate residues, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide

WO2021162567

Novel mRNA 5'-end cap analogs, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide

Publications about mRNA 5' cap modifications